Lora M Tablet

Montelukast, on the other hand, blocks leukotriene receptors, preventing the inflammatory response that contributes to bronchoconstriction and mucus production in conditions like asthma and allergic rhinitis. This dual-action formulation is particularly beneficial for patients experiencing both upper respiratory allergic symptoms and lower airway inflammation. Lora M Tablet is indicated for the management of seasonal and perennial allergic rhinitis, as well as prophylaxis and chronic treatment of asthma in patients requiring adjunctive therapy.

The combination enhances symptom control, improves quality of life, and may reduce the need for additional medication. It is generally well tolerated, with adverse effects being mild and infrequent. Use of Lora M should be under medical supervision, considering patient history and potential drug interactions. This tablet offers a convenient once-daily dosing regimen to optimize adherence and therapeutic outcomes in allergic disease management.